CN102101880A - Preparation method and application of radix astragali saponin - Google Patents
Preparation method and application of radix astragali saponin Download PDFInfo
- Publication number
- CN102101880A CN102101880A CN200910242526XA CN200910242526A CN102101880A CN 102101880 A CN102101880 A CN 102101880A CN 200910242526X A CN200910242526X A CN 200910242526XA CN 200910242526 A CN200910242526 A CN 200910242526A CN 102101880 A CN102101880 A CN 102101880A
- Authority
- CN
- China
- Prior art keywords
- radix astragali
- volume
- astragali saponin
- preparation
- saponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention provides a preparation method and application of radix astragali saponin. The preparation method of radix astragali saponin comprises the following steps: (1) adding water to radix astragali, extracting by decoction, filtering, and concentrating the filtrate; (2) adding ethanol to precipitate, and standing; (3) recovering the ethanol from the supernatant, diluting with water, injecting into macroporous adsorbent resin columns, and sequentially eluting with water, a 20% (volume/volume) ethanol water solution and a 70% (volume/volume) ethanol water solution; and (4) removing the ethanol in the eluent of the 70% (volume/volume) ethanol water solution, and drying to obtain the radix astragali saponin. The research indicates that the radix astragali saponin can activate the vascular endothelial cell NO-cGMP system, inhibit the calcium influx of vascular smooth muscle cells, and open the K[Ca] and K[ATP] channels, thereby relaxing the smooth muscles, especially vascular smooth muscles; and therefore, the radix astragali saponin has an obvious function of vasodilatation, and is suitable for preventing and treating cardiovascular diseases, such as lowering the blood pressure, resisting angina pectoris and the like.
Description
Technical field
The present invention relates to medical technical field, relate to a kind of preparation method and its usage of Radix Astragali saponin, particularly a kind of preparation method and its usage with Radix Astragali saponin of vasodilator effect.
Background technology
Essential hypertension is one of common disease, frequently-occurring disease of China's population, also is the important factor that forms cardiovascular and cerebrovascular diseases, and this is because the imbalance of vasoconstriction and diastolic function plays leading role to early stage generation, development and the complication of cardiovascular disorder.Hypertensive sickness rate increases day by day, and is very big to human health risk.At present, treating hypertensive drug main will be based on Western medicine, though onset is rapid, its drug dependence is strong, needs long-term prescription, and can produce some toxic side effect.And it is very few for Chinese medicine in the research aspect the treatment high blood pressure disease.
The Radix Astragali is one of the most frequently used Chinese medicinal materials, has the effect of tonifying Qi and lifting yang, inducing diuresis to remove edema, benefiting QI for strengthening the superficies, is widely used aspect preventing and treating in cardiovascular disorder.Modern pharmacology studies show that the Radix Astragali has the resistance of oxidation improving heart function, vasodilation, protection ischemic myocardium, improve body, improves effects such as hemodynamic index, anticoagulant and antithrombotic formation, is usually used in treatment of conditions such as coronary heart disease, hypertension, heart failure, viral myocarditis.Though the Radix Astragali has vasodilatory effect, its effect is also very limited and activeconstituents is still very not clear and definite, is one of important research project in the Chinese materia medica field at the research work of vasodilatory activeconstituents in the Radix Astragali always.
Summary of the invention
Therefore, the purpose of this invention is to provide a kind of from the Radix Astragali and have the medicine of more potent vasodilatory effect.
Be used to realize that the technical scheme of above-mentioned purpose is as follows:
A kind of preparation method of Radix Astragali saponin, it may further comprise the steps:
(1) Radix Astragali boiling is extracted, and filters concentrated filtrate;
(2) add ethanol and precipitate, leave standstill;
(3) thin up behind the supernatant liquor recovery ethanol injects macroporous adsorptive resins, water, 20% (volume/volume) aqueous ethanolic solution and 70% (volume/volume) aqueous ethanolic solution wash-out successively;
(4) remove ethanol in the elutriant of 70% (volume/volume) aqueous ethanolic solution, be drying to obtain.
In above-mentioned preparation method's step (1), decocting the number of times that extracts can be 3～5 times; The weight that adds water and the ratio of the weight of the Radix Astragali are for can 6～8; Extraction time can be 1.5～3 hours.
In above-mentioned preparation method's step (2), in adding alcoholic acid solution, the ethanol volume accounts for 80% of overall solution volume.
In above-mentioned preparation method's step (3), macroporous adsorbent resin is preferably nonpolar or the low-pole macroporous resin, more preferably HPD600 type macroporous adsorbent resin.
In a specific embodiments of the present invention, the preparation method of above-mentioned Radix Astragali saponin is: the deionized water heating that Radix Astragali medicine materical crude slice adds 10 times of weight decocts extraction 3 hours, filters filtrate for later use; The dregs of a decoction decoct and extract 2 times, and it adds water weight and is respectively 8 times and 6 times of Radix Astragali medicine materical crude slice weight, and extraction time was respectively 2.5 hours and 1.5 hours, filtration, and merging filtrate adds ethanol to ethanol volume and accounts for 80% of liquor capacity and carry out alcohol precipitation, leaves standstill 12 hours.The supernatant liquor decompression recycling ethanol is not distinguished the flavor of to there being alcohol, the gained concentrated solution adds the water dilution of 0.5 times of weight, filter, filtrate is injected in the macroporous adsorptive resins of having handled well slowly, use earlier the deionized water wash-out, use 20% (volume/volume) aqueous ethanolic solution wash-out of 2 times of column volume amounts again, discard the elutriant of 20% (volume/volume) aqueous ethanolic solution, use 70% (volume/volume) aqueous ethanolic solution wash-out of 4 times of weight again, collect the elutriant of 70% (volume/volume) aqueous ethanolic solution, reclaim ethanol to not having alcohol flavor, 60 ℃ of vacuum-dryings, pulverize, promptly get the Radix Astragali saponin extract.
The present invention also provides the Radix Astragali saponin of above-mentioned preparation method's preparation.Wherein, according to Radix Astragali saponin gross weight meter, Radix Astragali saponin comprises the Radix Astragali saponin III of Radix Astragali saponin II and 0.97% (weight) of Radix Astragali saponin I, 3.71% (weight) of the Cyclosiversioside F, 0.8% (weight) of 13.61% (weight).
The present invention also provides the purposes of above-mentioned Radix Astragali saponin in the vasodilatory medicine of preparation.Wherein, vasodilatory medicine is preferably the medicine that treats and/or prevents cardiovascular disorder, for example treats and/or prevents hypertension and/or anginal medicine.Preferably, vasodilatory medicine can activate vascular endothelial cell NO-cGMP system; Vasodilatory medicine can suppress stream in the outer calcium of vascular smooth muscle cell; Perhaps vasodilatory medicine can be realized K
CaAnd K
ATPThe opening of passage.
The present invention also provides a kind of vasodilatory pharmaceutical composition that is used for, and it comprises above-mentioned Radix Astragali saponin, and pharmaceutically acceptable carrier and/or vehicle.
The present invention also provides a kind of hypertensive pharmaceutical composition that is used for the treatment of, and it comprises above-mentioned Radix Astragali saponin, and pharmaceutically acceptable carrier and/or vehicle.
Aforementioned pharmaceutical compositions is preferably oral preparations.
The present invention is a research object with the known traditional Chinese medicine Radix Astragali with vasodilator effect, its activeconstituents has been carried out the screening and the tracking of system.Result of study of the present invention shows: being that crude drug has stronger diastolic blood vessel activity through the Radix Astragali saponin that extracts and purifying makes with the Radix Astragali, is most important effective constituent with vasodilator effect in the Radix Astragali.Given this, the present invention further studied and inquired into the vasodilatory mechanism of action of Radix Astragali saponin with and be used for the application of the medicine of vasodilator etc. in preparation.Up to now, relevant Radix Astragali saponin does not appear in the newspapers as yet to the pharmacological action and the mechanism of action thereof of blood vessel.
In order to observe the regulating effect of Radix Astragali saponin to blood vessel, the present invention adopts isolated rat thoracic aortic ring perfusion model, to get rid of in the experiment made on the living circulating hormone, neurotransmitter, the endothelium source property vasoactive factor etc. to the influence of its vasodilation effect.Found that, Radix Astragali saponin does not have effect to the vascular circle tension force of base state, and for phyenlephrinium (PE) (1 μ M) and KCl (35,60mM) pre-shrunk endothelium rat chest aorta vascular circle complete and that endothelium is removed all has significant diastole effect, and is better than the vascular circle that endothelium is removed for the effect of the complete vascular circle of endothelium.Show that the vasodilatory effect of Radix Astragali saponin partly depends on endothelium, may with the vascular relaxing factor of endothelium source property, relevant as nitrogen protoxide, prostacyclin etc.; With the exception of this, also may be to directly act on vascular smooth muscle and cause vasorelaxation.Above-mentioned result of study shows the inhibition of flowing in the outer calcium of activation, vascular smooth muscle cell of vascular endothelial cell NO-cGMP system, and K
CaAnd K
ATPThe open fellowship of passage the vasorelaxation action of Radix Astragali total saponins, based on the above-mentioned pharmacological action characteristics of Radix Astragali total saponins, but its relaxing smooth muscle, particularly vascular smooth muscle, be applicable to bring high blood pressure down, vascular conditions such as antianginal.
In sum, the present invention has successfully developed the new purposes of Radix Astragali saponin constituents in preparation vasodilator medicine in the traditional Chinese medicine Radix Astragali, has illustrated the inhibition of flowing in the outer calcium of activation, vascular smooth muscle cell of vascular endothelial cell NO-cGMP system, and K
CaAnd K
ATPThe opening of passage is one of vasodilatory vital role mechanism of Radix Astragali saponin, thereby utilizes the direct vasodilatory effect of Radix Astragali saponin, uses it among all kinds of related artery treatment of diseases.For the Radix Astragali, the curative effect of Radix Astragali saponin is stronger, and more helps the clinical treatment of all kinds of cardiovascular disordeies.
Description of drawings
Fig. 1 has shown the isolated rat thoracic aortic ring tensile influence of Radix Astragali saponin (EAM) to the pre-shrunk endothelium of KCl complete (E+);
Fig. 2 has shown Radix Astragali saponin (EAM) is removed (E-) to the pre-shrunk endothelium of KCl isolated rat thoracic aortic ring tensile influence;
Fig. 3 has shown that Radix Astragali saponin (EAM) is to the complete isolated rat thoracic aortic ring tensile influence of the pre-shrunk endothelium of PE;
Fig. 4 has shown the isolated rat thoracic aortic ring tensile influence that Radix Astragali saponin (EAM) is removed the pre-shrunk endothelium of PE;
Fig. 5 has shown after N-nitro L-arginine (L-NNA), Yamamoto Methylene Blue ZF (Methylene blue), indomethacin (Indomethacin) pre-treatment influence that Radix Astragali saponin (EAM) is made the diastole effect that the complete isolated rat thoracic aortic ring of the pre-shrunk endothelium of PE produces;
Fig. 6 shown triethylammonium tetrakis (tetraethylammonium, TEA), the influence of the diastole effect that produces of the isolated rat thoracic aortic ring that to Radix Astragali saponin (EAM) the pre-shrunk endothelium of PE removed after Glyburide (Glibenclamide) pre-treatment;
Fig. 7 has shown that no calcium liquid handles the influence of the diastole effect that back Radix Astragali saponin (EAM) produces the isolated rat thoracic aortic ring that the pre-shrunk endothelium of PE is removed;
Fig. 8 has shown the influence of the diastole effect that the back isolated rat thoracic aortic ring that the pre-shrunk endothelium of KCl is removed to Radix Astragali saponin (EAM) of no calcium liquid processing produces.
Embodiment
Describe the present invention in detail below in conjunction with specific embodiment, but these embodiment only are exemplary, scope of the present invention are not constituted any restriction.It will be understood by those skilled in the art that and down can make amendment or replace without departing from the spirit and scope of the present invention, but these modifications and replacing all fall within the scope of protection of the present invention the details of technical solution of the present invention and form.
Embodiment 1: the preparation of Radix Astragali saponin
Radix Astragali medicine materical crude slice adds 10 times of weight deionized water heating and decocts extraction 3 hours, filters filtrate for later use; The dregs of a decoction decoct and extract 2 times, and it adds water weight and is respectively 8 times and 6 times of Radix Astragali medicine materical crude slice weight, and extraction time was respectively 2.5 hours and 1.5 hours, filtration, and merging filtrate adds ethanol and is adjusted to the ethanol volume and accounts for 80% of liquor capacity and carry out alcohol precipitation, leaves standstill 12 hours.The supernatant liquor decompression recycling ethanol is not distinguished the flavor of to there being alcohol, the gained concentrated solution adds the water dilution of 0.5 times of weight, filter, filtrate is injected in the HPD600 type macroporous adsorptive resins of having handled well slowly, use earlier the deionized water wash-out, use 20% (volume/volume) aqueous ethanolic solution wash-out of 2 times of column volume amounts again, discard the elutriant of 20% (volume/volume) aqueous ethanolic solution, use 70% (volume/volume) aqueous ethanolic solution wash-out of 4 times of weight again, collect the elutriant of 70% (volume/volume) aqueous ethanolic solution, reclaim ethanol to not having alcohol flavor, vacuum-drying (60 ℃), pulverize, promptly get the Radix Astragali saponin extract.
The content assaying method of 4 main active ingredient is as follows in the above-mentioned Radix Astragali saponin extract:
Adopt high performance liquid chromatography to measure.
Mix the preparation of reference substance solution: it is an amount of accurately to take by weighing 4 kinds of reference substances, and dissolve with methanol is settled in the volumetric flask of 5ml.The concentration of each reference substance is respectively: Cyclosiversioside F 0.4mg/ml, Radix Astragali saponin I 0.25mg/ml, Radix Astragali saponin II 0.3mg/ml, Radix Astragali saponin III 0.27mg/ml.
The preparation of need testing solution: get above-mentioned Radix Astragali total saponins extract 100g,, be settled in the volumetric flask of 10ml with moving phase acetonitrile-water (volume ratio is 1: 4) dissolving, configuration concentration is the need testing solution of 10mg/ml, filter with 0.45 μ m millipore filtration, get subsequent filtrate, promptly.
Chromatographic condition and system suitability test: with the octadecylsilane chemically bonded silica is weighting agent; With the acetonitrile is mobile phase A, is Mobile phase B with water, carries out gradient elution by the elution requirement in the table 1; Flow velocity is 1.0ml/min; Adopt evaporation photodetector (ELSD) to detect, column temperature is 30 ℃.
The eluent gradient condition that table 1 HPLC finger printing detects
Assay method: accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing, inject liquid chromatograph, measure and calculation result (seeing Table 2).
Main active ingredient assay in table 2 Radix Astragali saponin
Embodiment 2: the preparation of isolated rat thoracic aortic ring
Adopt the male Sprague-Dawley of SPF level (SD) rat, body weight 240～260g.Rapidly free rat chest aorta places 4 ℃ with containing 95%O
2And 5%CO
2The pre-saturated K-H liquid of mixed gas in, reticular tissue around rejecting is cut into the vascular circle of 4-5mm, during notice that protection vascular circle inner membrance is not damaged.According to the experiment needs, adopt the method for cotton swab friction vascular circle internal surface, the part vascular circle is prepared into the model of removing endothelium.Then vascular circle is hung in the bath that presets 10ml K-H liquid, an end is fixed, and an end connects BIOPAC bio signal acquisition system (Biopac company, the U.S. by tonotransducer.Continuing logical 95%O
2-5%CO
2The state of mixed gas under, regulate its basic tension force to 2.0g, and stablize 60min down at 37 ℃.With KCl (60mmol/L) repetitive stimulation 3 times, to bring out the maximum shrinkage amplitude of blood vessel.After treating that vascular circle is stable again,, add vagusstoff (Ach) (10 μ mol/L) check blood vessel endothelium integrity with PE (1 μ mol/L) vasoconstriction ring peaking.If make the pre-shrunk vascular circle diastole of PE more than 70% after adding Ach, can think that endothelium is complete; Below 20%, think that then endothelium removes, wherein bringing out maximum shrinkage amplitude with PE (1 μ mol/L) or KCl (60mmol/L) is 100%, brings out the variation that ratio between the maximum shrinkage amplitude reacts antiotasis to add antiotasis amplitude and PE or KCl behind the medicine.
1. observe the influence of Radix Astragali total saponins to base state myocardium vessel ring strain
The Radix Astragali saponin of employing embodiment 1 preparation, according to accumulation dosing method, per 8～10min adds Radix Astragali saponin respectively 1 time, observes accumulation and gives the effect of the Radix Astragali saponin of 1～1000mg/L to endothelium complete sum endothelium removal vascular circle; Control group replaces appearance addings such as medicine with K-H liquid.
2. observe the effect of Radix Astragali saponin to KCl and the pre-shrunk myocardium vessel ring strain of PE
Complete at endothelium respectively, remove under the two states, (1～1000mg/L) to KCl (60mmol/L) and the influence of PE (1 μ mol/L) preshrinking vascular circle tensile to observe the cumulative concentration Radix Astragali total saponins; Control group replaces appearance addings such as medicine with K-H liquid.Come according to this comparison Radix Astragali saponin to have, the diastole effect of no interior cutaneous vessel ring.
3. result
(1) the accumulation Radix Astragali saponin that gives 1～1000 μ g/ml basic tension force complete to endothelium or the vascular circle removed does not all make significant difference;
(2) induce the vascular circle that the endothelium of contraction is complete or remove for KCl, each concentration Radix Astragali saponin all shows as concentration dependent diastole effect, and is better than the vascular circle (referring to Fig. 1-2) that endothelium is removed for the diastole effect of the complete vascular circle of endothelium;
(3) induce the vascular circle that the endothelium of contraction is complete or remove for PE, each concentration Radix Astragali saponin all shows as concentration dependent diastole effect, and the effect of the complete vascular circle of endothelium significantly is better than the effect (referring to Fig. 3-4) of endothelium being removed vascular circle.
In the above-mentioned experimental result, * P＜0.05, * * P＜0.01, * * * P＜0.001.
In view of Radix Astragali saponin has extremely significant diastole effect (P＜0.001) to KCl and the complete isolated rat thoracic aorta of the pre-shrunk endothelium of PE, for the mechanism of illustrating its effect has been carried out following experiment.
1. Radix Astragali saponin influences the complete vascular circle tensile of endothelium mechanism of action
To the complete vascular circle of endothelium, under K-H is hatched state, (1～1000mg/L) to L-NNA (0.1mmol/L) pre-treatment 30min, and methylene blue (10 μ mmol) pre-treatment 30min and indomethacin (10 μ mmol) pre-treatment 30min are to the influence of the effect of antiotasis to observe the cumulative concentration Radix Astragali saponin respectively.
2. Radix Astragali saponin influences endothelium removal vascular circle tensile mechanism of action
(1) potassium-channel blocker is to the influence of Radix Astragali saponin vasodilator effect
In the experiment of endothelium-denuded blood vessel, in the bath perfusate, add non-selective K
+The potassium-channel inhibitor Glyburide of channel blocker TEA (5mmol/L) or ATP sensitivity (10 μ mol/L), incubate bathe 30min after, add PE (1 μ mol/L), progressively increase the concentration of Radix Astragali saponin again, observe the vascular circle tensile and change.Control group replaces Radix Astragali saponin to incubate bath endothelium-denuded vascular circle with K-H liquid.
(2) in no calcium K-H liquid, PE is caused the influence of vascular circle contraction
In no calcium K-H liquid (adding 50 μ M EGTA in advance), incubate the vascular circle 20min that bathes endothelium-denuded, the no calcium K-H of the usefulness that continues liquid (not containing EGTA) flushing vascular circle 3 times, after the Radix Astragali saponin that the administration group adds 1000mg/L again after the balance is bathed 30min altogether, observe the restraining effect that its PE to 1 μ mol/L causes that vascular circle shrinks.Control group replaces Radix Astragali saponin to incubate bath endothelium-denuded vascular circle with K-H liquid.Observe the influence that calcium discharges in the Radix Astragali saponin pair cell thus.
(3) add the influence that in the K-H liquid of KCl calcium chloride is caused the vascular circle contraction in advance at no calcium
After at first in containing the no calcium K-H liquid (PE that adds 1 μ M concentration) of 1mmol/L EGTA, incubating bath endothelium-denuded vascular circle 60min, with no calcium K-H liquid flushing 3 times, incubate with no calcium K-H liquid (KCl that adds 60mM concentration in advance) and bathe about endothelium-denuded vascular circle 20 min, the Radix Astragali saponin that adds 1000mg/L is then bathed altogether and is observed it behind the 30min calcium chloride is caused the effect that vascular circle shrinks with different concns (0.1,0.5,1,1.5,2 and 2.5mM); After control group replaced Radix Astragali saponin to incubate bath endothelium-denuded vascular circle with K-H liquid, the calcium chloride solution that directly adds the concentration that adds up obtained the shrinkage curve of calcium chloride.Observe the influence of the outer flow of calcium ions of Radix Astragali saponin pair cell thus.
3. result
(1) as shown in Figure 5, for the complete vascular circle of endothelium, the Radix Astragali saponin vasorelaxation action of cumulative concentration can be blocked by L-NNA and methylene blue, and indomethacin can not be blocked the vasorelaxation action of Radix Astragali saponin.
(2) as shown in Figure 6, in the experiment of endothelium-denuded blood vessel, use K
+After channel blocker TEA (5mmol/L) qualifying row phenylureas (Gli) (10 μ mol/L) were incubated and bathed 30min, TEA, Gli all can significantly suppress the vasorelaxation action of Radix Astragali saponin.
(3) as shown in Figure 7, the vascular circle that Radix Astragali saponin is incubated bath causes that to the PE of 1 μ mol/L concentration vascular circle shrinks certain restraining effect is arranged, but not statistically significant (P＞0.05).
(4) as shown in Figure 8, the Radix Astragali saponin vascular circle of incubating bath obviously reduces (P＜0.01) to the caused contractile response of calcium chloride that adds different concns.
In the above-mentioned experimental result, * P＜0.05, * * P＜0.01, * * * P＜0.001.
This shows that Radix Astragali saponin has significant diastole effect to PE and the pre-shrunk rat chest aorta blood vessel of KCl.Wherein, the inhibition and the K of stream in the activation of vascular endothelial cell NO-cGMP system, the outer calcium of vascular smooth muscle cell
CaAnd K
ATPThe open fellowship of passage the vasorelaxation action of Radix Astragali saponin, proved that fully Radix Astragali saponin can be used for preparing the medicine of vasodilation.
Claims (16)
1. the preparation method of a Radix Astragali saponin, it may further comprise the steps:
(1) Radix Astragali boiling is extracted, and filters concentrated filtrate;
(2) add ethanol and precipitate, leave standstill;
(3) thin up behind the supernatant liquor recovery ethanol injects macroporous adsorptive resins, water, 20% (volume/volume) aqueous ethanolic solution and 70% (volume/volume) aqueous ethanolic solution wash-out successively;
(4) remove ethanol in the elutriant of 70% (volume/volume) aqueous ethanolic solution, be drying to obtain.
2. preparation method according to claim 1 is characterized in that, in step (1), the number of times that described decoction is extracted is 3～5 times.
3. preparation method according to claim 1 and 2 is characterized in that, in step (1), the described weight that adds water is 6～10: 1 with the ratio of the weight of the Radix Astragali.
4. according to each described preparation method in the claim 1 to 3, it is characterized in that in step (1), described extraction time is 1.5～3 hours.
5. according to each described preparation method in the claim 1 to 4, it is characterized in that in step (2), in adding alcoholic acid solution, the ethanol volume accounts for 80% of overall solution volume.
6. according to each described preparation method in the claim 1 to 5, it is characterized in that in step (3), described macroporous adsorbent resin is nonpolar or the low-pole macroporous resin, is preferably HPD600 type macroporous adsorbent resin.
7. according to the Radix Astragali saponin of each described preparation method preparation in the claim 1 to 6.
8. Radix Astragali saponin according to claim 7, it is characterized in that, according to the gross weight meter of Radix Astragali saponin, described Radix Astragali saponin comprises the Radix Astragali saponin III of Radix Astragali saponin II and 0.97% (weight) of Radix Astragali saponin I, 3.71% (weight) of the Cyclosiversioside F, 0.8% (weight) of 13.61% (weight).
9. according to claim 7 or the 8 described Radix Astragali saponins purposes in the vasodilatory medicine of preparation.
10. purposes according to claim 9, described vasodilatory medicine is the medicine that treats and/or prevents cardiovascular disorder, for example treats and/or prevents hypertension and/or anginal medicine.
11. according to claim 9 or 10 described purposes, described vasodilatory medicine can activate vascular endothelial cell NO-cGMP system.
12. according to claim 9 or 10 described purposes, described vasodilatory medicine can suppress stream in the outer calcium of vascular smooth muscle cell.
13. according to claim 9 or 10 described purposes, described vasodilatory medicine can be realized K
CaAnd K
ATPThe opening of passage.
14. one kind is used for vasodilatory pharmaceutical composition, it comprises according to claim 7 or 8 described Radix Astragali saponins, and pharmaceutically acceptable carrier and/or vehicle.
15. one kind is used for the treatment of hypertensive pharmaceutical composition, it comprises according to claim 7 or 8 described Radix Astragali saponins, and pharmaceutically acceptable carrier and/or vehicle.
16., it is characterized in that described pharmaceutical composition is an oral preparations according to claim 14 or 15 described pharmaceutical compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910242526 CN102101880B (en) | 2009-12-17 | 2009-12-17 | Preparation method and application of radix astragali saponin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910242526 CN102101880B (en) | 2009-12-17 | 2009-12-17 | Preparation method and application of radix astragali saponin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102101880A true CN102101880A (en) | 2011-06-22 |
| CN102101880B CN102101880B (en) | 2013-06-12 |
Family
ID=44154969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910242526 Active CN102101880B (en) | 2009-12-17 | 2009-12-17 | Preparation method and application of radix astragali saponin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102101880B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102232962A (en) * | 2011-07-25 | 2011-11-09 | 苏州大学 | Composition containing astragaloside active components as well as preparation method and application thereof |
| CN104586872A (en) * | 2015-01-06 | 2015-05-06 | 李子林 | Medicine composition for preventing and treating vascular endothelial dysfunction and application thereof |
| CN105213262A (en) * | 2015-10-29 | 2016-01-06 | 苏建华 | A kind of NO/cGMP protease cell neogenesis stock solution and preparation method thereof |
| CN110693937A (en) * | 2019-10-23 | 2020-01-17 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Application of astragalus and pseudo-ginseng composition as medicine for relieving acute liver injury caused by triptolide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557329A (en) * | 2004-01-18 | 2004-12-29 | 成都厚发科技开发有限公司 | Medicine composition for treating cardiovascular and cerebrovascular disease and its prepararing method |
| CN1682862A (en) * | 2005-02-24 | 2005-10-19 | 四川科伦药业股份有限公司 | Method for preparing astragalus root saponin |
-
2009
- 2009-12-17 CN CN 200910242526 patent/CN102101880B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557329A (en) * | 2004-01-18 | 2004-12-29 | 成都厚发科技开发有限公司 | Medicine composition for treating cardiovascular and cerebrovascular disease and its prepararing method |
| CN1682862A (en) * | 2005-02-24 | 2005-10-19 | 四川科伦药业股份有限公司 | Method for preparing astragalus root saponin |
Non-Patent Citations (1)
| Title |
|---|
| 王旭慧等: "黄芪甲苷对正常大鼠离体血管功能的影响", 《中国药理学通报》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102232962A (en) * | 2011-07-25 | 2011-11-09 | 苏州大学 | Composition containing astragaloside active components as well as preparation method and application thereof |
| CN102232962B (en) * | 2011-07-25 | 2013-03-06 | 苏州大学 | Composition containing astragaloside active components as well as preparation method and application thereof |
| CN104586872A (en) * | 2015-01-06 | 2015-05-06 | 李子林 | Medicine composition for preventing and treating vascular endothelial dysfunction and application thereof |
| CN105213262A (en) * | 2015-10-29 | 2016-01-06 | 苏建华 | A kind of NO/cGMP protease cell neogenesis stock solution and preparation method thereof |
| CN110693937A (en) * | 2019-10-23 | 2020-01-17 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Application of astragalus and pseudo-ginseng composition as medicine for relieving acute liver injury caused by triptolide |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102101880B (en) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1781107B1 (en) | Herbal pharmaceutical compositions for prophylaxis and/or treatment of cardiovascular diseases and the method of preparing the same | |
| CN101219161B (en) | Dracocephalum moldavica extract and dracocephalum moldavica dropping pills, and method of preparing the same | |
| CN101214270B (en) | Acanthopanax senticosus effective fraction extract, preparation and application thereof | |
| CN101085728A (en) | Method for preparing paeonol and paeoniflorin from cortex moutan | |
| CN102101880B (en) | Preparation method and application of radix astragali saponin | |
| CN104725450B (en) | A kind of method that high-purity oleuropein is extracted from jasmine | |
| CN102641317A (en) | Golden wave extract and application thereof in preparation of antidiabetic agent | |
| CN102327309B (en) | Barberry bark extractive and use of barberry bark extractive and barberry bark | |
| CN101057890B (en) | Traditional Chinese medicinal composition for treating coronary heart disease and its preparation method, preparations and its application | |
| CN108210566A (en) | A kind of limonin extract is preparing the application in treating diabetes medicament | |
| CN103191289A (en) | Synchronous preparation method of four effective parts in medicine pair of common anemarrhena rhizome and amur corktree bark and application thereof | |
| CN102100737B (en) | Medicinal composition containing general ginsenoside and total salvianolic acid and preparation method thereof | |
| CN102526138B (en) | Composition of active components from fresh purslane for decreasing blood sugar and preparation method | |
| CN1990500B (en) | Application of siatic centella triterpenoid saponin for preparing medicine for treating hepatic fibrosis | |
| CN107349244A (en) | Application in the extracting method and treatment diabetic nephropathy of malonyl ginsenoside | |
| CN101597314B (en) | Preparation method of ginsenoside Rg1 | |
| CN101549010B (en) | A preparing method and application of malaytea scurfpea fruit total glycosides extract | |
| CN112684053B (en) | Method for simultaneously determining content of 7 components in anti-chronic heart failure medicine compound | |
| CN100584358C (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN1321651C (en) | Oral cavity spray containing two effective parts of compound red sage root formula and its preparation process | |
| CN102430001B (en) | Compound rose-hip flavone preparation for preventing diabetes mellitus and preparation method thereof | |
| CN102198183A (en) | Pharmaceutical composition for treating apoplexy, preparation method thereof and application thereof | |
| CN111358800A (en) | Application of two phenylethanoid glycoside compounds in preparation of antidiabetic drugs | |
| CN101912565B (en) | Turmeric and astragalus capsules for treating diabetes and incipient diabetic nephropathy | |
| CN105641169B (en) | A kind of Dengyin naotong pharmaceutical composition and its new application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |